<DOC>
	<DOCNO>NCT01885611</DOCNO>
	<brief_summary>To date , clinical investigation effect virgin coconut oil ( VCO ) oral supplementation patient Hansen 's disease ( HD ) undergo medical treatment . This study aim examine possible protective effect exogenous supplementation VCO oxidative stress , antioxidant status , treatment response among HD patient . Treatment response define clinical change cutaneous neurologic manifestation measure clinical response score . This study also aim investigate potential VCO adjunct Multi-Drug Therapy ( MDT ) mitigate lepra reaction .</brief_summary>
	<brief_title>Virgin Coconut Oil Oral Supplementation Leprosy Patients</brief_title>
	<detailed_description>Objective : To determine effect co-administration virgin coconut oil ( VCO ) oral supplementation standard Multi-Drug Therapy ( MDT ) malondialdehyde ( MDA ) , superoxide dismutase ( SOD ) , glutathione ( GSH ) blood level determine compare treatment response leprosy case treat MDT alone case treat MDT VCO supplementation . Design : This open label , control clinical trial preliminary/phase 1 trial . Setting : Patients see out-patient clinic Section Dermatology , Philippine General Hospital , tertiary government hospital . Participants : Twenty-six previously untreated Hansen 's Disease ( HD ) patient , 18 year old , diagnose clinically confirm histologically HD . Intervention : The 26 HD patient divide two group : group 1 receive MDT group 2 receive MDT VCO supplementation . Both group 1 2 consist 6 7 Paucibacillary ( PB ) patient 6 7 Multibacillary ( MB ) patient . All participant MDA , SOD , GSH blood level take initial consult third sixth month . Treatment response measure clinical response score , grade blind investigator base cutaneous manifestation ( change , moderate improvement , definite improvement , bad ) neurologic manifestation ( change , improvement , bad ) . Main Outcome Measures : The mean inter-quartile range MDA , SOD , GSH blood level ; bacterial index ( BI ) morphological index ( MI ) slit skin-smears ; treatment response base clinical response score . Frequency severity lepra reaction also note . Data Analysis : The following statistical test use : Mann-Whitney test compare difference median value group 1 group 2 ; Kruskal-Wallis Test multiple comparison ; Wilcoxon sign rank test comparing difference median value within group ; Fisher 's exact test compare frequency categorical data treatment response ( cutaneous manifestation ) ; T test quantitative data ( neurologic manifestation ) use . Values p &lt; 0.05 consider statistically significant .</detailed_description>
	<mesh_term>Leprosy</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Dapsone</mesh_term>
	<mesh_term>Clofazimine</mesh_term>
	<mesh_term>Lactitol</mesh_term>
	<criteria>Patients age 18 year , male female Patients clinical evidence histological confirmation lepromatous leprosy ( LL ) , borderline lepromatous leprosy ( BL ) , borderline leprosy ( BB ) , borderline tuberculoid leprosy ( BT ) , tuberculoid leprosy ( TT ) accord Ridley Jopling classification Paucibacillary ( PB ) Multibacillary ( MB ) disease base World Health Organization ( WHO ) classification Patients MDT past Patients normal blood test result complete blood count ( CBC ) , liver aminotransaminases ( AST , ALT ) , glucose6phosphate dehydrogenase ( G6PD ) assay , creatinine , lipid profile chest xray HD patient reaction need prednisone therapy time diagnosis Patients already take VCO oral intravenous antioxidant supplement Patients take long term medication unrelated leprosy Pregnant woman Patients history smoking , coinfections tuberculosis , diabetes mellitus , systemic disease health problem Patients willing return followup</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Leprosy</keyword>
</DOC>